ESMO WCGIC 2020 | Anti-PD-L1/TGF-β trap in non-HPV associated HNSCC

Jason Redman, MD, National Cancer Institute, Bethesda, MD, outlines the rationale behind a Phase I/II study evaluating M7824, a bifunctional immunotherapy consisting of a TGF‑β trap and anti-PD-L1, with or without TriAd vaccine and N-803, for p16-negative resectable head and neck squamous cell carcinoma (HNSCC) not associated with HPV infection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).